BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)
A biotechnology company, which designs, optimizes and develops novel drugs that block key enzymes involved in cancer, cardiovascular diseases, autoimmune diseases, and viral infections.
- Quote
- Commentary
- Scorecard
- Historical Prices
- Chart
- Stats
- Ratios
- Earnings/Growth Rates
- Statements
- SEC Filings
Recs
With bird flu season around the corner, news should pick back up on it and more of a focus will be made on the companies in that sector. BCRX is beaten down to the point it makes a good potential acquisition candidate too.
Recs
Over sold, improving technicals, fundamentals.
Recs
Clear leader in bird flu technologies.
Recs
over sold great speculation
Recs
Only waiting for
1. Paramarvir to go GA
2. Bird Flu hit US.
After that, will take profits
Recs
breakthrough medication if birdflu breaks out
Recs
It's not a matter of if, but when, the stock goes to 0. My pick is for an outbreak of 0 in Asia first, followed by Canada, then lastly America.
Recs
Several promising products in pipe. Recent government funding for Peramavir, like Tamiflu but better. Possible M or A target.
Recs
New products coming, plus it will rise if avian flu concerns increase.
Recs
Biotech company developing drugs that block key enzymes involved in cancer, heart diseases, autoimmune diseases, and viral infections
Recs
lets put it this way its not a matter of if but when the avian flu will come to america in the human population.asia will be first i,m predicting this year will get the first big outbreak. if i was you i,d buy some tami flu like now.
Recs
Bird Flu drug
Recs
whose chicken ?
Recs
If I could short rational drug design I would. But I can't, so this will have to do in the meantime.
Don't get me wrong. I'm all for solving structures and playing with the active site. But with this sort of strategy I think the odds of success are better if you play the lottery.
So, based on my bias against rationally-designed drugs as good investments, this short pick is my bet that fodosine will yield lackluster clinical results.
Recs
killed by cramer
Recs
Biocryst (BRCX) pharma is a small biopharmaceutical company that has already established a name in the antivirals segment, especially with their leading bird-flu vaccination. Although this is a volatile stock, i predict this company to either partner or be bought out by other giants such as Roche or Astra Zeneca; The valuation is fair and the stock has dropped about 50% since the beginning of this year. So a good time to buy this aggressive growth stock.
RSS Headlines
Fool UK
- Show Me:
-
Outperform
-
Underperform
-
All
- Sort by:
-
Author
-
Recs
-
Date
-
Member Rating
-
Results 21 - 36 of 36 : « Previous 1 2